UnitedHealth Group Inc. — Q1 2014 Form 10-Q
Reporting period: Three months ended March 31, 2014; financial statements are unaudited. UnitedHealth Group operates UnitedHealthcare, providing health coverage and benefits services, and Optum, providing information- and technology-enabled health services.
Financial results and condition
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Revenue | $31.708 billion | $30.340 billion | Up 5% |
| Operating earnings | $2.054 billion | $2.139 billion | Down 4% |
| Net earnings attributable to UHG shareholders | $1.099 billion | $1.192 billion | Down 8% |
| Diluted EPS | $1.10 | $1.16 | Down 5% |
| Operating margin | 6.5% | 7.1% | Down 0.6 percentage points |
| Medical care ratio | 82.5% | 82.7% | Down 0.2 percentage points |
| Operating cost ratio | 16.4% | 15.2% | Up 1.2 percentage points |
| Effective tax rate | 42.0% | 36.8% | Up 5.2 percentage points |
| Operating cash flow | $1.408 billion | $1.053 billion | Up $355 million |
Revenue growth reflected expansion in public and senior markets and Optum. Premium revenue rose 3%; services revenue rose 14%; and product revenue rose 33%. Optum revenue increased 29%, led by OptumRx, while UnitedHealthcare revenue grew 4%. Operating earnings at UnitedHealthcare fell 12%, partly offset by 20% growth at Optum. OptumRx operating earnings more than doubled, while OptumHealth and OptumInsight operating earnings declined.
At March 31, 2014, cash and cash equivalents were $7.514 billion, short- and long-term investments totaled approximately $21.2 billion, and total assets were $84.622 billion. The company reported $1.0 billion of cash available for general corporate use. Current liabilities were $30.716 billion. Commercial paper and current maturities of long-term debt were $2.241 billion; long-term debt was $14.524 billion. The company had $1.124 billion of commercial paper outstanding and no borrowings under its $4.0 billion revolving credit facilities. It was in compliance with debt covenants; its debt-to-debt-plus-equity ratio was 34.0%.
Cash increased $238 million during the quarter, ending at $7.514 billion. Investing activities used $603 million and financing activities used $573 million. Cash uses included $911 million of share repurchases, $276 million of dividends, $345 million for acquisitions, and $353 million for property, equipment and capitalized software. The declared quarterly dividend was $0.28 per share.
Material changes and management outlook
- Operating costs rose 13%, faster than revenue, reflecting ACA-related fees, a greater mix of services business, and investments for growth. Medical costs increased 3%.
- The nondeductible ACA Industry Tax was estimated at $1.3 billion for 2014; the company recorded the full estimated liability at the start of the year and amortizes the related cost through the year. Management expected this tax to increase the 2014 effective tax rate by about 500 basis points. The company also estimated approximately $0.5 billion of 2014 reinsurance-program contributions, payable in 2015.
- Management estimated ACA fees and related tax effects reduced Q1 EPS by $0.30, sequestration by $0.05, and Medicare Advantage funding actions by more than $0.10. ACA fees lowered the reported medical care ratio but increased the operating cost ratio and tax rate.
- Management estimated Medicare Advantage funding reductions and the Industry Tax would reduce full-year 2014 consolidated net earnings by approximately $1.3 billion versus 2013, before mitigation actions. It cited further Medicare Advantage payment reductions in 2015 and expected pressure on Medicare earnings in 2014 and 2015. Medicaid margins were also expected to remain under reimbursement-rate pressure.
- Management expected $1.4–$1.6 billion of additional annual premiums in 2014 from pricing in reform fees and related tax impacts. It expected no material financial-statement impact from the ACA risk adjustment, risk corridors, or premium stabilization programs. No specific full-year EPS or revenue guidance is stated in the supplied filing text.
- Commercial risk-based membership declined 4%, with management citing disciplined pricing, competition, and movement of some individual customers to exchanges. The company exited certain Medicare Advantage markets and plans affecting approximately 150,000 beneficiaries served in 2013.
Risks, contingencies and unusual items
- Medical cost reserve development was favorable by $220 million, compared with $280 million in Q1 2013; the lower year-over-year benefit weighed on results.
- A California insurance claims-processing matter remained before the state Insurance Commissioner. The regulator had advocated a penalty of approximately $325 million, while a nonbinding administrative-law-judge proposal recommended a nonmaterial penalty. The company said it could not reasonably estimate any loss.
- A Nevada jury award of $524 million in an endoscopy-center case was reduced by the trial court to $366 million and was being appealed. The company also faced 41 individual lawsuits and two class actions related to the outbreak; it could not reasonably estimate potential losses.
- Government audits and investigations include Medicare risk-adjustment data validation reviews, which may result in retrospective payment adjustments; the company could not reasonably estimate potential losses from material reviews.
- Key business risks include medical cost estimation and pricing, health-care regulation and reimbursement, competitive pressures, litigation and government reviews, privacy and cybersecurity, investment and interest-rate exposure, and Brazilian real currency movements. The filing reported no material changes to the risk factors in the 2013 Form 10-K.
Important facts for investors to verify
- How ACA taxes, reinsurance contributions, exchange enrollment and pricing affect full-year costs, margins and cash flows.
- The realized earnings and membership effects of Medicare Advantage funding reductions, plan exits, benefit changes and quality ratings.
- Whether OptumRx growth and other Optum investments can offset pressure in UnitedHealthcare and sustain segment profitability.
- Developments in the California and Nevada matters, Medicare audits, and other regulatory or legal contingencies.
- Cash availability and capital allocation: only $1.0 billion of reported cash was available for general corporate use at quarter-end, alongside ongoing repurchases, dividends and debt obligations.